TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30573151

Group type: EXPERIMENTAL
Intervention: Support for nutrition policy implementation
Number of subjects: 595

Group type: COMPARATOR
Intervention: Support for physical activity policy implementation
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Nutrition condition
Number of subjects: 595
Study: 28536308

Group type: COMPARATOR
Intervention: GM-CSF
Number of subjects: 815

Group type: COMPARATOR
Intervention: Melanoma peptide vaccine
Number of subjects: 815

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 815

Group type: COMPARATOR
Intervention: GM-CSF and/or peptide vaccine
Number of subjects: 815
Study: 25886927

Group type: EXPERIMENTAL
Intervention: Triggered cell phone reminders and counseling using objective adherence data
Number of subjects: 120

Group type: COMPARATOR
Intervention: No reminders or data-informed counseling
Number of subjects: 120
Study: 23452375

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (200 to 400 mg daily for 12 months)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 252
Study: 21575016

Group type: EXPERIMENTAL
Intervention: XR-NTX 380 mg
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Lead-in abstinence (n = 82)
Number of subjects: 624

Group type: COMPARATOR
Intervention: No lead-in abstinence (n = 542)
Number of subjects: 624
Study: 19524839

Group type: EXPERIMENTAL
Intervention: Self-etching system (SEP) - Transbond Plus SEP, 3M Unitek
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional multi-step system (TBXT) - Transbond XT, 3M Unitek
Number of subjects: 28
Study: 17149552

Group type: EXPERIMENTAL
Intervention: One Fleet enema 2 h pre-procedure (Group 1)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Two Fleet enemas (one on the evening prior and one 2 h pre-procedure) (Group 2)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Lactulose 30 ml orally 48 and 24 h prior to sigmoidoscopy, plus a single Fleet enema 2 h pre-procedure (Group 3)
Number of subjects: 305
Study: 15529135

Group type: EXPERIMENTAL
Intervention: Stainless steel tip at full power (SS-FP)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Diamond tip at full power (D-FP)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Stainless steel tip at half power (SS-HP)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Diamond tip at half power (D-HP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (only apically resected teeth)
Number of subjects: 45
Study: 10573832

Group type: EXPERIMENTAL
Intervention: LIFT (Linking the Interests of Families and Teachers) intervention
Number of subjects: 671

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 671
Study: 8917241

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (30 or 60 mg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (20 or 37.5 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (for both pseudoephedrine and phenylpropanolamine)
Number of subjects: 41
Study: 1842943

Group type: COMPARATOR
Intervention: VVI pacing at a rate of 30 beats/min
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: VVI pacing at a rate of 70 beats/min
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Physiological DDD or QT pacing
Number of subjects: 18

Group type: COMPARATOR
Intervention: Physiological pacing vs standard ventricular pacing
Number of subjects: 18
Study: 6626441

Group type: EXPERIMENTAL
Intervention: Alinidine 40 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Clonidine 0.1 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30222511

Group type: EXPERIMENTAL
Intervention: Remote international virtual network (RIVN) mentoring during tube thoracostomy insertion.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Unmentored tube thoracostomy insertion.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Remote telementoring (RTM) experience.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mentor opinion on safety of TT procedures.
Number of subjects: 14
Study: 27916327

Group type: EXPERIMENTAL
Intervention: One-year increase in grade attainment in Uganda
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Grade attainment in Malawi
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Grade attainment in both countries
Number of subjects: 1441
Study: 25581388

Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy with standard intra-abdominal pressure (IAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic donor nephrectomy with low intra-abdominal pressure (IAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy
Number of subjects: 0
Study: 22932716

Group type: EXPERIMENTAL
Intervention: Vorapaxar (2.5 mg daily)
Number of subjects: 17779

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17779
Study: 20417924

Group type: COMPARATOR
Intervention: Staples
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Subcuticular sutures
Number of subjects: 180
Study: 18798083

Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg oral administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15621375

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (0.08‐8 ms, 2‐200 Hz)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Histamine iontophoresis (100 microC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Number of subjects: 30
Study: 15115973

Group type: EXPERIMENTAL
Intervention: UDCA (4 mg/kg per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10604506

Group type: EXPERIMENTAL
Intervention: comprehensive geriatric assessment and post‐discharge home intervention
Number of subjects: 545

Group type: COMPARATOR
Intervention: comprehensive geriatric assessment alone
Number of subjects: 545

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 545
Study: 8611058

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Coping skills therapy (with placebo)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Supportive therapy (with placebo)
Number of subjects: 80
Study: 1960234

Group type: EXPERIMENTAL
Intervention: CPITN
Number of subjects: 52
Study: 6347750

Group type: EXPERIMENTAL
Intervention: 3-day clotrimazole treatment (200 mg once a day for 3 consecutive days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6-day clotrimazole treatment (100 mg once a day for 6 consecutive days)
Number of subjects: 0
Study: 31246713

Group type: EXPERIMENTAL
Intervention: Running on a treadmill
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cycling on a cycle ergometer
Number of subjects: 38
Study: 29735467

Group type: EXPERIMENTAL
Intervention: Small dose mifepristone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 0
Study: 26432913

Group type: EXPERIMENTAL
Intervention: 50μg gE/AS01B formulation (HZ/su)
Number of subjects: 129
Study: 24281294

Group type: EXPERIMENTAL
Intervention: PACSLAC-II
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preexisting pain assessment tools
Number of subjects: 0
Study: 22898028

Group type: EXPERIMENTAL
Intervention: Domperidone gel (1.1 mg/kg, PO, once daily)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Domperidone gel
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 35
Study: 20714379

Group type: EXPERIMENTAL
Intervention: Farcosolvin syrup (ambroxol 15 mg, theophylline 50 mg, guaiphenesin 30 mg per 5 mL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (guaiphenesin treatment)
Number of subjects: 100
Study: 17975955

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser with AH Plus cement
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diode laser with AH Plus cement
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser with EndoREZ cement
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diode laser with EndoREZ cement
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no laser treatment) with AH Plus cement
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no laser treatment) with EndoREZ cement
Number of subjects: 80
Study: 17314442

Group type: EXPERIMENTAL
Intervention: 5% topical tea tree oil gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15036669

Group type: EXPERIMENTAL
Intervention: Flutamide 750mg daily
Number of subjects: 309

Group type: COMPARATOR
Intervention: No adjuvant treatment (Control)
Number of subjects: 309
Study: 11271856

Group type: EXPERIMENTAL
Intervention: Biscuit with synthetic beta-carotene
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Biscuit with red palm oil
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo biscuit
Number of subjects: 265
Study: 9179054

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 47
Study: 1304212

Group type: EXPERIMENTAL
Intervention: 1.0% prednisolone acetate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.1% dexamethasone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated fellow-eyes
Number of subjects: 20
Study: 3883441

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no indomethacin)
Number of subjects: 28
Study: 30688558

Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1%
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Nepafenac 0.3%
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 29991347

Group type: COMPARATOR
Intervention: Sertraline 50 mg/day
Number of subjects: 2011

Group type: COMPARATOR
Intervention: Sertraline 100 mg/day
Number of subjects: 2011

Group type: COMPARATOR
Intervention: Continue sertraline
Number of subjects: 2011

Group type: EXPERIMENTAL
Intervention: Add mirtazapine
Number of subjects: 2011

Group type: EXPERIMENTAL
Intervention: Switch to mirtazapine
Number of subjects: 2011
Study: 26914134

Group type: COMPARATOR
Intervention: Methoxamine 2 mg alone (Group M)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Methoxamine 2 mg with atropine 0.1 mg (Group MA1)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Methoxamine 2 mg with atropine 0.2 mg (Group MA2)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Methoxamine 2 mg with atropine 0.3 mg (Group MA3)
Number of subjects: 160

Group type: COMPARATOR
Intervention: All groups (M, MA1, MA2, MA3)
Number of subjects: 160
Study: 24355994

Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation (PNS) for 3 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 25
Study: 22799559

Group type: EXPERIMENTAL
Intervention: Moderate renal insufficiency (CKD with eGFR <60)
Number of subjects: 6209

Group type: EXPERIMENTAL
Intervention: Participants categorized by CKD status and BMI groups
Number of subjects: 6209
Study: 20623289

Group type: EXPERIMENTAL
Intervention: 10 cc 1% Lignocaine at apical region (Group B)
Number of subjects: 386

Group type: COMPARATOR
Intervention: No anaesthesia (Group A)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: 5 cc 1% Lignocaine at both bases (Group C)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: 4 cc at apex and 3 cc at both bases (Group D)
Number of subjects: 386
Study: 17981854

Group type: EXPERIMENTAL
Intervention: Supervised in-laboratory time of 64 hours over 10 days (SD = 2.6)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Task-specific practice schedule
Number of subjects: 35
Study: 16377604

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 279

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 279
Study: 12496753

Group type: EXPERIMENTAL
Intervention: Semisimultaneous administration of midazolam (5 mg orally followed by 2 mg IV after 6 hours)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketoconazole administration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional method (individual midazolam doses, 1 week apart)
Number of subjects: 12
Study: 9752816

Group type: EXPERIMENTAL
Intervention: Educational interventions (teleconference, small group workshops, newsletters)
Number of subjects: 4403

Group type: COMPARATOR
Intervention: Media impacts (adverse news about CCBs)
Number of subjects: 4403

Group type: COMPARATOR
Intervention: CCB or ACE inhibitor as first-line therapy
Number of subjects: 4403
Study: 7657846

Group type: EXPERIMENTAL
Intervention: Cibenzoline 260 mg/day
Number of subjects: 68

Group type: COMPARATOR
Intervention: Flecainide 200 mg/day
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Cibenzoline
Number of subjects: 68

Group type: COMPARATOR
Intervention: Flecainide
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Cibenzoline and Flecainide
Number of subjects: 68
Study: 2720134

Group type: EXPERIMENTAL
Intervention: Whole 240 mg verapamil sustained-release tablet
Number of subjects: 12
Study: 773086

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31525490

Group type: EXPERIMENTAL
Intervention: Child care-center based lessons (18-week gross motor and 12-week nutrition) administered by trained child care staff
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Web-based intervention for caregivers in addition to center-based lessons
Number of subjects: 864

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 864
Study: 28990161

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided axillary vein cannulation
Number of subjects: 132

Group type: COMPARATOR
Intervention: Landmark-guided subclavian vein cannulation
Number of subjects: 132
Study: 26984901

Group type: EXPERIMENTAL
Intervention: Combined treatment with Albendazole (ABZ) 15 mg/k/d for 10 days and Praziquantel (PZQ) 50 mg/k/d for 10 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Albendazole (ABZ) alone 15 mg/k/d for 10 days
Number of subjects: 32
Study: 24717377

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Choice of treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Pharmacotherapy with sertraline
Number of subjects: 200
Study: 23043965

Group type: EXPERIMENTAL
Intervention: Indirect moxibustion 2 times per week for 4 weeks (Treatment group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Indirect moxibustion 3 times per week for 4 weeks (Treatment group B)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Current lifestyle maintenance (Control group)
Number of subjects: 45
Study: 19704392

Group type: EXPERIMENTAL
Intervention: History of sexual abuse in the past year
Number of subjects: 665

Group type: COMPARATOR
Intervention: No history of sexual abuse
Number of subjects: 665
Study: 17469667

Group type: EXPERIMENTAL
Intervention: Non-weight-bearing single-joint quadriceps exercise (SJNWBE)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Weight-bearing multiple-joint quadriceps exercise (MJWBE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 45
Study: 16036041

Group type: EXPERIMENTAL
Intervention: Aldosterone blockade (specific drug not mentioned, but refers to Aldactone and Eplerenone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12915929

Group type: EXPERIMENTAL
Intervention: Continuous three‐lead orthogonal ECG monitoring in PTCA patients
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Continuous three‐lead orthogonal ECG monitoring in ACS patients
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard 100 μV threshold
Number of subjects: 55
Study: 10557001

Group type: EXPERIMENTAL
Intervention: Salt restriction diet (5 grams of sodium chloride per day) with oral and written instructions from a clinical nutritionist and provision of low sodium bread (0.5%) during weeks 4-24.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Salt restriction diet (5 grams of sodium chloride per day).
Number of subjects: 39
Study: 8739026

Group type: EXPERIMENTAL
Intervention: Grapefruit juice with quinidine sulfate (400 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water with quinidine sulfate (400 mg)
Number of subjects: 12
Study: 1902054

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (Streptokinase or rt-PA)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study: 7132728

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Cimetidine (400 mg) after placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg) after Cimetidine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Thyrotropin-releasing hormone (25 micrograms) after placebo or Met
Number of subjects: 19
Study: 30898325

Group type: EXPERIMENTAL
Intervention: CBT/TC/TXT
Number of subjects: 55

Group type: COMPARATOR
Intervention: SG
Number of subjects: 55
Study: 27046445

Group type: EXPERIMENTAL
Intervention: Trabodenoson (200, 400, 800, 1,600, 2,400, or 3,200 μg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Trabodenoson
Number of subjects: 60
Study: 24861853

Group type: EXPERIMENTAL
Intervention: USL255 (topiramate) extended-release capsules, single doses ranging from 25-1,400 mg
Number of subjects: 0
Study: 22594648

Group type: COMPARATOR
Intervention: Homeopathic remedy (Sulphur or Pulsatilla) at potencies of 6c, 12c, or 30c, presented in a randomized order over 3 sessions.
Number of subjects: 97
Study: 19161631

Group type: EXPERIMENTAL
Intervention: Weight‐bearing balance and strengthening exercises with cueing strategies for freezing of gait (intervention group)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Usual‐care control group
Number of subjects: 230
Study: 17909382

Group type: EXPERIMENTAL
Intervention: Designed delays (DD) trial of nebulizer-to-inhaler conversion policy
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Designed delays (DD) trial of reduced restrictions on Cox-2 inhibitors
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Researchers' recollections of their degree of influence on decisions
Number of subjects: 104
Study: 16330739

Group type: EXPERIMENTAL
Intervention: Ventilation tube (VT) treatment
Number of subjects: 113

Group type: COMPARATOR
Intervention: Medical treatment (no ventilation tubes)
Number of subjects: 113
Study: 11986409

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy (metoprolol or carvedilol)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 9455713

Group type: EXPERIMENTAL
Intervention: Carbamazepine slow-release formulation with food
Number of subjects: 24

Group type: COMPARATOR
Intervention: Carbamazepine slow-release formulation without food (12-hour fast)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Carbamazepine slow-release formulation (both conditions)
Number of subjects: 24
Study: 7963067

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 79
Study: 3671253

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30617388

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:00.000 adrenaline
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 3% prilocaine with felypressin 0.03 I.U. per ml
Number of subjects: 96
Study: 29433613

Group type: EXPERIMENTAL
Intervention: Indicated medication for schizophrenia or mood disorders along with usual prayer camp activities (prayers, chain restraints and fasting)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Prayer camp activities alone (no medication)
Number of subjects: 139
Study: 27793431

Group type: EXPERIMENTAL
Intervention: PACT intervention
Number of subjects: 152
Study: 24717790

Group type: EXPERIMENTAL
Intervention: Formoterol pMDI 2.25 micrograms
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Formoterol pMDI 4.5 micrograms
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Formoterol pMDI 9 micrograms
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Formoterol dry powder inhaler 12 micrograms (active comparator)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 23046709

Group type: EXPERIMENTAL
Intervention: Intranasal 17β estradiol 3 mg/day for two months + 200 mg/day of micronized progesterone by vaginal route 14 days/month (E2+P)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Percutaneous 17β estradiol gel 1.5 mg/day for three months + 200 mg/day of micronized progesterone by vaginal route 14 days/month (E2+P)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Intranasal 17β estradiol 3 mg/day for two months (E2)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Percutaneous 17β estradiol gel 1.5 mg/day for three months (E2)
Number of subjects: 86
Study: 19578221

Group type: EXPERIMENTAL
Intervention: Plaferone LB
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard program of intensive therapy
Number of subjects: 40
Study: 17804681

Group type: EXPERIMENTAL
Intervention: Recruitment to a clinical trial (no change in therapy)
Number of subjects: 1040
Study: 15096911

Group type: EXPERIMENTAL
Intervention: Alcohol (0.65 g/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 11241092

Group type: EXPERIMENTAL
Intervention: 30 mg/kg intravenous methylprednisolone during sternotomy and 30 mg/kg during initiation of cardiopulmonary bypass
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 15 mg/kg methylprednisolone at the same 2 times
Number of subjects: 90

Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution at the same 2 times
Number of subjects: 90
Study: 9706371

Group type: EXPERIMENTAL
Intervention: Idebenone 300 mg t.i.d.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Idebenone (various dosages from 60 mg to 300 mg t.i.d.)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: COMPARATOR
Intervention: Piracetam 800 mg t.i.d.
Number of subjects: 17